PrimeGen US Secures $1.5 Billion SPAC Merger to Advance Triple-Activated Stem Cell Platform for Acute Liver Injury
核心洞察
PrimeGen US (搜索) announced a $1.5 billion merger with DT Cloud Star Acquisition Corporation (搜索) to advance its Triple Activated Mesenchymal Stem Cell platform for acute liver injury (搜索) treatment.
The company completed a Pre-IND meeting with the FDA in December 2025 for Acute Alcoholic Hepatitis (搜索), marking progress toward potential clinical trials.
The transaction is expected to close in the second half of 2026, providing public market access and capital for clinical development and regulatory activities.
PrimeGen US (搜索), a regenerative medicine company developing stem cell therapies for acute liver conditions, announced a definitive business combination agreement with DT Cloud Star Acquisition Corporation (搜索) valued at approximately $1.5 billion in equity. The transaction, announced February 4, 2026, represents one of the larger SPAC deals in the biotech sector and is expected to provide the combined company with access to public market capital for advancing clinical development programs.
The California-based biotech has spent nearly two decades developing its proprietary Triple Activated Mesenchymal Stem Cell (MSC) platform as a novel cell-based treatment for acute liver injury (搜索) and related critical conditions. The platform has demonstrated preclinical activity in animal studies, though the company cautioned that preclinical results may not be indicative of clinical outcomes in humans.
Regulatory Progress and Clinical Development Plans
PrimeGen US (搜索) achieved a significant regulatory milestone with the completion of a Pre-Investigational New Drug application (Pre-IND) meeting with the U.S. Food & Drug Administration on December 17, 2025, focusing on Acute Alcoholic Hepatitis (搜索) (Acute Liver Failure (搜索)). The company is working toward initiating a clinical trial, subject to regulatory approval, to support further development of Triple Activated MSCs for the potential treatment of this condition.
However, the company emphasized that "there can be no assurance that the FDA will allow an IND to proceed or that any clinical trials will be successful." Despite having nearly two decades of foundational stem cell research, PrimeGen has not yet entered clinical trials with its lead programs.
Transaction Structure and Timeline
The merger with DT Cloud Star, a publicly traded special purpose acquisition company (Nasdaq (搜索): DTSQ), is subject to approval by stockholders of both companies, receipt of required regulatory approvals including compliance with the Hart-Scott-Rodino Antitrust Improvements Act if applicable, satisfaction of minimum cash conditions, and other customary closing conditions. The transaction is currently expected to close in the second half of 2026.
Upon closing, the combined company is expected to operate as PrimeGen US (搜索) and is anticipated to list on Nasdaq (搜索) under a new ticker symbol, subject to Nasdaq approval. DT Cloud Star went public in July 2024, raising $69 million.
Leadership Perspectives
"We are thrilled to partner with DT Cloud Star to bring PrimeGen US (搜索) into the public markets at this pivotal moment," said Daniel Chiu, Co-CEO and Chairman of PrimeGen US. "This transaction is expected to enhance our access to capital and resources, supporting the continued development of our stem cell and exosome programs."
Wai Szeto, Co-CEO of PrimeGen US (搜索), added: "With nearly two decades of foundational stem cell technology as our launchpad, we have developed our Triple Activated MSC platform into a differentiated platform under development that we believe is well positioned to advance through its next stages of development, subject to regulatory review."
Sam Zheng Sun, Chairman and CEO of DT Cloud Star Acquisition Corporation (搜索), expressed confidence in the partnership: "We have great confidence that under the leadership of Co-CEOs Daniel Chiu and Wai Szeto, the company is uniquely positioned to deliver much-needed regenerative medicine to treat challenging diseases, such as acute liver failure (搜索)."
Platform Technology and Market Position
PrimeGen US (搜索) positions itself as leveraging nearly two decades of proprietary stem cell research to develop its Triple Activated MSC platform. The company's focus on acute liver injury (搜索) represents an approach to addressing critical medical conditions through regenerative medicine, though clinical validation remains pending.
The biotech cautioned in its regulatory filings that the inherent uncertainty of clinical success presents risks, and trials may be delayed or fail to meet primary endpoints. Additionally, the possibility exists that FDA or other regulatory authorities may not approve candidates or may require additional data before proceeding with clinical development.